United Therapeutics Corporation (UTHR) key performance indicators and operating metrics (18 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Tyvaso Dry Powder Inhaler net product sales | 330.3M | FY2026-Q1 |
| Adcirca net product sales | 2.9M | FY2026-Q1 |
| Orenitram net product sales | 135.6M | FY2026-Q1 |
| Nebulized Tyvaso net product sales | 127.2M | FY2026-Q1 |
| Other net product sales | 5.3M | FY2026-Q1 |
| Remodulin net product sales | 126.6M | FY2026-Q1 |
| Unituxin net product sales | 53.6M | FY2026-Q1 |
| Effective income tax rate | 14.00 percent | FY2026-Q1 |
| Tyvaso revenues | 464.3M | FY2025-Q4 |
| Orenitram | 121M | FY2025-Q4 |
| Remodulin | 128M | FY2025-Q4 |
| Trailing twelve months operating cash flow | 1.6M | FY2025-Q4 |
| Unituxin | 62M | FY2025-Q4 |
| Other plus Adcirca percent change | 14M | FY2025-Q4 |
Back to UTHR overview · UTHR earnings · UTHR holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.